Alnodesertib

Alnodesertib
Clinical data
Other namesGTPL13731; BDBM570448; ART-0380; IACS-030380
Identifiers
  • 4-[4-[(cyclopropyl-methyl-oxo-λ6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC18H24N6O2S
Molar mass388.49 g·mol−1
3D model (JSmol)
  • C[C@@H]1COCCN1C2=NC(=NC(=C2)N=[S@](=O)(C)C3CC3)C4=CC(=NC=C4)N
  • InChI=InChI=1S/C18H24N6O2S/c1-12-11-26-8-7-24(12)17-10-16(23-27(2,25)14-3-4-14)21-18(22-17)13-5-6-20-15(19)9-13/h5-6,9-10,12,14H,3-4,7-8,11H2,1-2H3,(H2,19,20)/t12-,27+/m1/s1
  • Key:JHPDHYAMSPMBIF-MUDIAHQHSA-N

Alnodesertib is an investigational new drug that is being developed by Artios Pharma for the treatment of solid tumours.[1][2] It is an ataxia telangiectasia and Rad3 related (ATR) protein inhibitor.[1][3][4]

Clinical trials

Alnodesertib is currently in clinical trials for solid tumors.[5] Another study was terminated "not for reasons affecting the benefit-risk balance".[6]

References

  1. ^ a b "Alnodesertib - Artios Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ "WHO proposed international nonproprietary names list" (PDF). World Health Organization. Retrieved 3 July 2026.
  3. ^ Qin S, An J, Qiao W, Zhichao X, Siyao T, Seo G, et al. (June 2026). "Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 201 119670. doi:10.1016/j.biopha.2026.119670. PMID 42314345.
  4. ^ Kciuk M, Wanke K, Marciniak B, Kołat D, Aleksandrowicz M, Mujwar S, et al. (January 2026). "Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature". International Journal of Molecular Sciences. 27 (3): 1152. doi:10.3390/ijms27031152. PMC 12898043. PMID 41683580.
  5. ^ Clinical trial number NCT04657068 NCT04657068 for "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov
  6. ^ Clinical trial number NCT05798611 for "Study of ART0380 in Patients With Biologically Selected Solid Tumors" at ClinicalTrials.gov
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.